Bernstein has reiterated its underperform rating on BioNTech, casting a shadow over the German biotechnology firm's experimental cancer treatment pumitamig. The investment bank's note, released on Tuesday, highlights concerns around the drug's clinical profile, including potential safety issues and uncertain efficacy data that could limit its commercial potential. BioNTech shares dipped 2.3% to €119.40 in early Frankfurt trading, reflecting investor unease.
Pumitamig, a bispecific antibody targeting solid tumours, is one of BioNTech's most closely watched pipeline assets. Bernstein's analysts argue that recent trial results have not demonstrated a clear advantage over existing therapies, and that regulatory hurdles could delay approval. The note comes as broader European biotech indices remain under pressure, with the STOXX Europe 600 Health Care index down 0.8% on the day.
For UK investors, the development matters because BioNTech is a significant holding in several actively managed investment trusts and pension funds focused on healthcare innovation. The company's reliance on pumitamig to diversify beyond its COVID-19 vaccine revenue stream has been a key narrative for shareholders. Any setback could weigh on the stock's valuation, which already trades at a premium to peers based on future earnings expectations.
Analysts at other houses have been more cautious, with some noting that pumitamig's mechanism of action remains novel and could still prove effective in specific patient subgroups. However, Bernstein's stance underscores the high-risk nature of biotech investing, where late-stage trial failures can wipe billions off market capitalisations. The FTSE 100 was flat on the day, but the broader market mood was subdued amid rising bond yields.
For UK pension holders with exposure to global equity funds, the BioNTech rating serves as a reminder of the volatility inherent in healthcare stocks. While the company's cash position remains strong, the path to profitability from its pipeline is far from assured. Investors should monitor upcoming pumitamig data readouts, expected in the second half of 2025, for clearer signals.